Search Within

GDMT, Medicine

  1. "Early Drug Development Service"
Formats
  1. Journal Article (42)
  2. Meeting Abstract (29)
  3. Book Section (1)
Groups
  1. Department of Medicine (72)
  2. Early Drug Development Service (72)
  3. Gynecologic Medicine Service (72)
  4. Gynecology Disease Management Team (72)
  5. Solid Tumor Oncology Division (72)
  6. Epidemiology and Biostatistics (35)

More Groups

People
  1. David Hyman (61)
  2. Carol Aghajanian (36)
  3. Rachel Grisham (33)
  4. Vicky Makker (25)
  5. Martee Hensley (24)
  6. Alexia Iasonos (23)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (1)
  4. 2022 (3)
  5. 2021 (2)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (21)
  2. Gynecologic Oncology (10)
  3. Clinical Cancer Research (8)
  4. JCO Precision Oncology (5)
  5. Annals of Oncology (3)
  6. Cancer (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (26)
  2. Elsevier Inc. (13)
  3. American Association for Cancer Research (12)
  4. Lippincott Williams & Wilkins (5)
  5. Oxford University Press (3)
  6. Springer (3)

More Publishers

Results (72)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer
    Journal Article

    Stasenko, M.; Tunnage, I.; Ashley, C. W.; Rubinstein, M. M.; Latham, A. J.; Da Cruz Paula, A.; Mueller, J. J.; Leitao, M. M. Jr; Friedman, C. F.; Makker, V.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Response to selective RET inhibition with LOXO-292 in a patient with RET fusion-positive lung cancer with leptomeningeal metastases
    Journal Article

    Guo, R.; Schreyer, M.; Chang, J. C.; Rothenberg, S. M.; Henry, D.; Cotzia, P.; Kris, M. G.; Rekhtman, N.; Young, R. J.; Hyman, D. M.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer
    Journal Article

    Cadoo, K. A.; Mandelker, D. L.; Mukherjee, S.; Stewart, C.; DeLair, D.; Ravichandran, V.; Srinivasan, P.; Hurley, D.; Kemel, Y.; Arnold, A. G.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • A phase 2 study of TPIV200/ huFR-1 (a multi-epitope folate receptor alpha vaccine) in combination with durvalumab in patients with platinum resistant ovarian cancer
    Meeting Abstract

    Zamarin, D.; Yeku, O.; O'Cearbhaill, R. E.; Cadoo, K. A.; Gallagher, J.; Kravetz, S.; McDonnell, A.; Troso-Sandoval, T.; Sabbatini, P.; Lichtman, S.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • First-in-human phase I study of the activin A inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors
    Journal Article

    Tao, J. J.; Cangemi, N. A.; Makker, V.; Cadoo, K. A.; Liu, J. F.; Rasco, D. W.; Navarro, W. H.; Haqq, C. M.; Hyman, D. M.
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: An interim analysis of a multicentre, open-label, single-arm, phase 2 trial
    Journal Article

    Makker, V.; Rasco, D.; Vogelzang, N. J.; Brose, M. S.; Cohn, A. L.; Mier, J.; Di Simone, C.; Hyman, D. M.; Stepan, D. E.; Dutcus, C. E.; more...
    Lancet Oncology (2019)

    Fulltext@MSK | Save
  • Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
    Journal Article

    Boland, J. L.; Zhou, Q.; Martin, M.; Callahan, M. K.; Konner, J.; O'Cearbhaill, R. E.; Friedman, C. F.; Tew, W.; Makker, V.; Grisham, R. N.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers
    Meeting Abstract

    Li, B. T.; Makker, V.; Buonocore, D. J.; Offin, M. D.; Olah, Z. T.; Panora, E.; Shen, R.; Ho, A. L.; Yaeger, R.; Iyer, G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer
    Meeting Abstract

    Friedman, C. F.; Donoghue, M.; Vivek, M.; Aghajanian, C.; Abu-Rustum, N.; Cadoo, K. A.; Grisham, R. N.; Hensley, M. L.; Konner, J. A.; Kyi, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase Ib study of miransertib (ARQ 092) in combination with anastrozole in patients with PIK3CA or AKT1-mutant ER+ endometrial or ovarian cancer
    Meeting Abstract

    Hyman, D.; Bonafede, M.; O'Cearbhaill, R.; Grisham, R.; Zamarin, D.; Tew, W.; Aghajanian, C.; Cadoo, K.; Friedman, C.; Savage, R. E.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save